"Advanced NSCLC" trang 1 - tải miễn phí từ tailieuXANH
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: A German retrospective data analysis

Real-world treatment and survival of patients with advanced non-small cell lung Cancer: A German retrospective data analysis
14    60    0
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials
17    48    0
Báo cáo y học:

Báo cáo y học: "Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients"
6    35    0
Ebook Fast facts - Non-small-cell lung cancer: Part 2

Ebook Fast facts - Non-small-cell lung cancer: Part 2
49    54    0
Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples

Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples
10    54    0
Intratumoral heterogeneity of EGFRactivating mutations in advanced NSCLC patients at the single-cell level

Intratumoral heterogeneity of EGFRactivating mutations in advanced NSCLC patients at the single-cell level
8    50    0
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study
11    55    0
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
10    63    0
Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): Findings from a real-world setting

Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): Findings from a real-world setting
8    128    0
Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinumbased chemotherapy: A meta-analysis based on the PRISMA statement

Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinumbased chemotherapy: A meta-analysis based on the PRISMA statement
13    76    0
Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: A retrospective cohort study

Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: A retrospective cohort study
17    56    0
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review

Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review
7    78    0
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using reallife data

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using reallife data
11    337    1
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1- rearranged advanced non-small cell lung cancer (NSCLC) in Canada

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1- rearranged advanced non-small cell lung cancer (NSCLC) in Canada
13    70    1
Investigating efficacy of “microbiota modulation of the gut-lung Axis” combined with chemotherapy in patients with advanced NSCLC: Study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial

Investigating efficacy of “microbiota modulation of the gut-lung Axis” combined with chemotherapy in patients with advanced NSCLC: Study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial
8    38    1
An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC)

An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC)
8    221    2
Clinical and economic impact of ‘ROS1- testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

Clinical and economic impact of ‘ROS1- testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
13    25    1
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.